<DOC>
	<DOCNO>NCT02526329</DOCNO>
	<brief_summary>This phase I trial study side effect best dose donor regulatory T cell treat patient graft-versus-host disease affect liver gastrointestinal organ ( visceral ) within 100 day ( acute ) undergo stem cell transplant . Graft-versus-host disease occur donor immune cell infused stem cell transplant attack gut , skin , liver , organ system patient . Regulatory T cell type immune cell may able reduce attack donor 's immune cell patient 's normal cell help treat graft-vs-host disease .</brief_summary>
	<brief_title>Donor Regulatory T Cells Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine safety feasibility donor T regulatory ( Treg ) cell infusion subject visceral acute graft-versus-host disease ( aGVHD ) incidence dose limit toxicity ( DLTs ) grade accord Common Terminology Criteria Adverse Events ( CTCAE version 4 [ v.4 ] ) focus infusion reaction within 24 hour , respiratory distress within 72 hour infusion all-cause mortality within 28 day infusion . SECONDARY OBJECTIVES : I . Determine quantitative blood Treg cell change follow cell infusion . II . Assess dose requirement treatment response rate primary steroid , secondary tertiary immunosuppressive therapy . III . Post-transplant day +100 day +180 survival . IV . Post-transplant incidence chronic graft-versus-host disease ( GVHD ) day +180 . OUTLINE : This dose-escalation study . Patients receive donor regulatory T lymphocytes intravenously ( IV ) 5 minute less day 0 . Some patient receive second infusion frozen donor regulatory T lymphocytes 5-7 day initial infusion 2 additional infusion separate 5-7 day . After completion study treatment , patient follow weekly day 28 day 100 180 .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Visceral aGVHD define : least stage III/IV acute liver stage II/III gastrointestinal ( GI ) GVHD clinical criterion and/or GI and/or liver biopsy confirmation show alternative explanation symptom GVHD Ability understand willingness sign write informed consent form Must 7/8 8/8 haploidentical relate donor match human leukocyte antigen ( HLA ) A , B , C , DRB1 evaluate provide donor transplant graft Myeloablative nonmyeloablative allogeneic hematopoietic cell transplantation Karnofsky performance status &gt; = 50 DONOR : Age &gt; = 18 = &lt; 77 year old DONOR : Karnofsky performance status &gt; = 70 % define institutional standard DONOR : Must sibling donor recipient 's blood marrow graft collect original allogeneic transplant HLA 7/8 8/8 haploidentical match HLAA , B , C , DRB1 DONOR : Serologies human immunodeficiency virus ( HIV ) antigen ( Ag ) , HIV 1 HIV 2 antibody ( Ab ) , human Tcell lymphotropic virus ( HTLV ) 1 HTLV 2 Ab , hepatitis B surface antigen ( sAg ) polymerase chain reaction ( PCR ) + , hepatitis C Ab PCR+ , syphilis ( Treponema ) screen HIV 1 hepatitis C NAT ( nucleic acid test ) collect prior apheresis DONOR : Female donor childbearing potential must negative serum urine betahuman chorionic gonadotropin ( HCG ) test within two week apheresis DONOR : Capable undergoing leukapheresis , adequate venous access , willing undergo insertion central catheter leukapheresis via peripheral vein inadequate DONOR : Donor selection compliance 21 Code Federal Regulations ( CFR ) 1271 Uncontrolled infection responsive antimicrobial therapy require intensive critical care Progressive malignant disease , include posttransplant lymphoproliferative disease unresponsive therapy Cytomegalovirus colitis enteritis define cytomegalovirus ( CMV ) shell vial culture positivity endoscopic biopsy discretion treat physician base upon PCR positivity , clinical presentation histology Respiratory insufficiency oxygen requirement &gt; 4 L nasal cannula Multiorgan failure DONOR : Evidence active infection viral hepatitis DONOR : HIV positive DONOR : Pregnant donor DONOR : Factors place donor increase risk complication leukapheresis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>